ArticleJournal of nephrology2025
Characteristics and clinical courses of patients with atypical haemolytic uraemic syndrome on dialysis withdrawal after eculizumab treatment: sub-analysis of post-marketing surveillance in Japan.
Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtypical haemolytic uraemic syndrome (aHUS) leads to acute kidney injury, necessitating dialysis in about half of patients. A certain proportion of patients treated with C5 inhibitors discontinue dialysis; however, little is known about the patient characteristics and clinical courses relating to discontinuation.
methodsWe compared the characteristics and clinical courses of patients with aHUS on dialysis at the initiation of eculizumab during post-marketing surveillance in Japan, stratified by those who did (Group A) and did not (Group B) discontinue dialysis within 26 weeks of eculizumab treatment.
resultsOf 38 included patients, 21 (55.3%) and 17 (44.7%) were placed in Groups A and B, respectively. No patient re-started dialysis. Hypertension was less frequent in Group A than in Group B (6/21 [28.6%] vs. 11/17 [64.7%], p = 0.022). Both the duration of dialysis before eculizumab initiation (6 vs. 17 days, p = 0.011) and the time from thrombotic microangiopathy onset to eculizumab initiation (9 vs. 25 days, p = 0.008) were shorter in Group A. A duration of less than 15 days from thrombotic microangiopathy onset to eculizumab initiation was associated with dialysis discontinuation. Kidney function improvement and normalisation of platelet count and lactate dehydrogenase levels were achieved earlier in Group A than in Group B (p = 0.050, 0.014, and < 0.001, respectively). Five (29.4%) of 17 patients in Group B discontinued dialysis after 27 weeks of eculizumab treatment, including one patient who underwent kidney transplantation.
conclusionsEarly initiation of eculizumab was significantly correlated with dialysis discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.